Literature DB >> 23775124

LIM-only protein FHL2 activates NF-κB signaling in the control of liver regeneration and hepatocarcinogenesis.

Jennifer Dahan1, Yann Nouët, Grégory Jouvion, Florence Levillayer, Minou Adib-Conquy, Anne-Marie Cassard-Doulcier, Ali Tebbi, Fany Blanc, Lauriane Remy, Ju Chen, Stefano Cairo, Catherine Werts, Mustapha Si-Tahar, Thierry Tordjmann, Marie-Annick Buendia, Yu Wei.   

Abstract

Four-and-a-half LIM-only protein 2 (FHL2) is an important mediator in many signaling pathways. In this study, we analyzed the functions of FHL2 in nuclear factor κB (NF-κB) signaling in the liver. We show that FHL2 enhanced tumor necrosis factor (TNF) receptor-associated factor 6 (TRAF6) activity in transcriptional activation of NF-κB targets by stabilizing the protein. TRAF6 is a binding partner of FHL2 and an important component of the Toll-like receptor-NF-κB pathway. Knockdown of FHL2 in 293-hTLR4/MD2-CD14 cells impaired lipopolysaccharide (LPS)-induced NF-κB activity, which regulates expression of inflammatory cytokines. Indeed, FHL2(-/-) macrophages showed significantly reduced production of TNF and interleukin 6 (IL-6) following LPS stimulation. TNF and IL-6 are the key cytokines that prime liver regeneration after hepatic injury. Following partial hepatectomy, FHL2(-/-) mice exhibited diminished induction of TNF and IL-6 and delayed hepatocyte regeneration. In the liver, NF-κB signaling orchestrates inflammatory cross talk between hepatocytes and hepatic immune cells that promote chemical hepatocarcinogenesis. We found that deficiency of FHL2 reduced susceptibility to diethylnitrosamine-induced hepatocarcinogenesis, correlating with the activator function of FHL2 in NF-κB signaling. Our findings demonstrate FHL2 as a positive regulator of NF-κB activity in liver regeneration and carcinogenesis and highlight the importance of FHL2 in both hepatocytes and hepatic immune cells.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23775124      PMCID: PMC3753919          DOI: 10.1128/MCB.00105-13

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  44 in total

Review 1.  NF-κB and STAT3 - key players in liver inflammation and cancer.

Authors:  Guobin He; Michael Karin
Journal:  Cell Res       Date:  2010-12-28       Impact factor: 25.617

2.  Hepatocyte IKKbeta/NF-kappaB inhibits tumor promotion and progression by preventing oxidative stress-driven STAT3 activation.

Authors:  Guobin He; Guann-Yi Yu; Vladislav Temkin; Hisanobu Ogata; Christian Kuntzen; Toshiharu Sakurai; Wolfgang Sieghart; Markus Peck-Radosavljevic; Hyam L Leffert; Michael Karin
Journal:  Cancer Cell       Date:  2010-03-16       Impact factor: 31.743

3.  Deletion of NEMO/IKKgamma in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma.

Authors:  Tom Luedde; Naiara Beraza; Vasileios Kotsikoris; Geert van Loo; Arianna Nenci; Rita De Vos; Tania Roskams; Christian Trautwein; Manolis Pasparakis
Journal:  Cancer Cell       Date:  2007-02       Impact factor: 31.743

4.  Deficiency of the LIM-only protein FHL2 reduces intestinal tumorigenesis in Apc mutant mice.

Authors:  Charlotte Labalette; Yann Nouët; Florence Levillayer; Sabine Colnot; Ju Chen; Valere Claude; Michel Huerre; Christine Perret; Marie-Annick Buendia; Yu Wei
Journal:  PLoS One       Date:  2010-04-28       Impact factor: 3.240

5.  Tumor necrosis factor receptor-associated factor 6 is an intranuclear transcriptional coactivator in osteoclasts.

Authors:  Shuting Bai; Jikun Zha; Haibo Zhao; F Patrick Ross; Steven L Teitelbaum
Journal:  J Biol Chem       Date:  2008-09-03       Impact factor: 5.157

6.  Human four-and-a-half LIM family members suppress tumor cell growth through a TGF-beta-like signaling pathway.

Authors:  Lihua Ding; Zhaoyun Wang; Jinghua Yan; Xiao Yang; Aijun Liu; Weiyi Qiu; Jianhua Zhu; Juqiang Han; Hao Zhang; Jing Lin; Long Cheng; Xi Qin; Chang Niu; Bin Yuan; Xiaohui Wang; Cui Zhu; Yan Zhou; Jiezhi Li; Haifeng Song; Cuifen Huang; Qinong Ye
Journal:  J Clin Invest       Date:  2009-01-12       Impact factor: 14.808

Review 7.  NF-kappaB signaling, liver disease and hepatoprotective agents.

Authors:  B Sun; M Karin
Journal:  Oncogene       Date:  2008-10-20       Impact factor: 9.867

8.  Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production.

Authors:  Willscott E Naugler; Toshiharu Sakurai; Sunhwa Kim; Shin Maeda; Kyounghyun Kim; Ahmed M Elsharkawy; Michael Karin
Journal:  Science       Date:  2007-07-06       Impact factor: 47.728

9.  Enhanced expression of FHL2 leads to abnormal myelopoiesis in vivo.

Authors:  Z Qian; L Mao; A A Fernald; H Yu; R Luo; Y Jiang; J Anastasi; P J Valk; R Delwel; M M Le Beau
Journal:  Leukemia       Date:  2009-04-16       Impact factor: 11.528

10.  The Patched dependence receptor triggers apoptosis through a DRAL-caspase-9 complex.

Authors:  Frédéric Mille; Chantal Thibert; Joanna Fombonne; Nicolas Rama; Catherine Guix; Hideki Hayashi; Véronique Corset; John C Reed; Patrick Mehlen
Journal:  Nat Cell Biol       Date:  2009-05-24       Impact factor: 28.824

View more
  18 in total

1.  Differential Effects of Estrogen Receptor β Isoforms on Glioblastoma Progression.

Authors:  Jinyou Liu; Gangadhara R Sareddy; Mei Zhou; Suryavathi Viswanadhapalli; Xiaonan Li; Zhao Lai; Rajeshwar R Tekmal; Andrew Brenner; Ratna K Vadlamudi
Journal:  Cancer Res       Date:  2018-04-16       Impact factor: 12.701

2.  LIM-Only Protein FHL2 Is a Negative Regulator of Transforming Growth Factor β1 Expression.

Authors:  Jennifer Dahan; Florence Levillayer; Tian Xia; Yann Nouët; Catherine Werts; Martine Fanton d'Andon; Minou Adib-Conquy; Anne-Marie Cassard-Doulcier; Varun Khanna; Ju Chen; Thierry Tordjmann; Marie-Annick Buendia; Grégory Jouvion; Yu Wei
Journal:  Mol Cell Biol       Date:  2017-05-02       Impact factor: 4.272

3.  Identification of gene regulation patterns underlying both oestrogen- and tamoxifen-stimulated cell growth through global gene expression profiling in breast cancer cells.

Authors:  Ping Fan; Heather E Cunliffe; Obi L Griffith; Fadeke A Agboke; Pilar Ramos; Joe W Gray; V Craig Jordan
Journal:  Eur J Cancer       Date:  2014-09-15       Impact factor: 9.162

4.  FHL2 interacts with EGFR to promote glioblastoma growth.

Authors:  Lili Sun; Shuye Yu; Hui Xu; Yanwen Zheng; Juntang Lin; Meiyan Wu; Jide Wang; Aidong Wang; Qing Lan; Frank Furnari; Webster Cavenee; Benjamin Purow; Ming Li
Journal:  Oncogene       Date:  2018-01-11       Impact factor: 9.867

5.  Transcriptional regulation of the tumor suppressor FHL2 by p53 in human kidney and liver cells.

Authors:  Jiaying Xu; Junwei Zhou; Man-Shan Li; Chor-Fung Ng; Yuen-Keng Ng; Paul Bo-San Lai; Stephen Kwok-Wing Tsui
Journal:  PLoS One       Date:  2014-08-14       Impact factor: 3.240

6.  FHL3 Contributes to EMT and Chemotherapy Resistance Through Up-Regulation of Slug and Activation of TGFβ/Smad-Independent Pathways in Gastric Cancer.

Authors:  Guodong Cao; Pengping Li; Xiaobo He; Mengyao Jin; Mengying Li; Sihan Chen; Xin Xu; Qiang Sun; Maoming Xiong; Bo Chen
Journal:  Front Oncol       Date:  2021-06-04       Impact factor: 6.244

7.  The LIM-only protein FHL2 attenuates lung inflammation during bleomycin-induced fibrosis.

Authors:  Abdulaleem Alnajar; Carolin Nordhoff; Tanja Schied; Ruth Chiquet-Ehrismann; Karin Loser; Thomas Vogl; Stephan Ludwig; Viktor Wixler
Journal:  PLoS One       Date:  2013-11-18       Impact factor: 3.240

8.  FHL2 regulates hematopoietic stem cell functions under stress conditions.

Authors:  Y Hou; X Wang; L Li; R Fan; J Chen; T Zhu; W Li; Y Jiang; N Mittal; W Wu; D Peace; Z Qian
Journal:  Leukemia       Date:  2014-09-02       Impact factor: 11.528

9.  Differences in the expression of chromosome 1 genes between lung telocytes and other cells: mesenchymal stem cells, fibroblasts, alveolar type II cells, airway epithelial cells and lymphocytes.

Authors:  Xiaoru Sun; Minghuan Zheng; Miaomiao Zhang; Mengjia Qian; Yonghua Zheng; Meiyi Li; Dragos Cretoiu; Chengshui Chen; Luonan Chen; Laurentiu M Popescu; Xiangdong Wang
Journal:  J Cell Mol Med       Date:  2014-05       Impact factor: 5.310

10.  Deficiency of multidrug resistance 2 contributes to cell transformation through oxidative stress.

Authors:  Ali Tebbi; Florence Levillayer; Grégory Jouvion; Laurence Fiette; Guillaume Soubigou; Hugo Varet; Nesrine Boudjadja; Stefano Cairo; Kosuke Hashimoto; Ana Maria Suzuki; Piero Carninci; Annamaria Carissimo; Diego di Bernardo; Yu Wei
Journal:  Carcinogenesis       Date:  2015-11-05       Impact factor: 4.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.